Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background: Cytomegalovirus (CMV) viremia is associated with mortality in severely ill immunocompetent adults and hospitalized children with HIV (CWH). We measured CMV viremia in HIV-exposed and -unexposed Kenyan children aged 1-59 months discharged from hospital and determined its relationship with post-discharge mortality. Methods: CMV DNA levels were measured in plasma from 872 HIV-unexposed, 97 HIV-exposed-uninfected (HEU), and 15 CWH aged <5 years. Poisson and Cox proportional hazards Regression models were used to identify correlates of CMV viremia >1000 IU/ml and estimate associations with 6-month mortality, respectively. Results: CMV viremia was detected in 31% of children, with levels >1000 IU/ml in 5.8%. HIV infection, age <2 years, breastfeeding, and mid-upper arm circumference<12.5cm were associated with CMV viremia >1000 IU/ml. Among HEU children, CMV >1000 IU/ml (HR=32.0 [95%CI=2.9-354.0], p=0.005) and each 1-log increase in CMV viral load (HR=5.04 [95%CI=1.7, 14.6], p=0.003) were associated with increased risk of mortality. CMV viremia was not significantly associated with mortality in HIV-unexposed children. Conclusions: CMV levels at hospital discharge predict increased risk of 6-month mortality in Kenyan HEU children. CMV suppression may be a novel target to reduce mortality in this high-risk population.



Journal of Infectious Diseases


Infectious Diseases Society of America

Publication Date



FFR, child mortality, post-discharge mortality, azithromycin, cytomegalovirus, HIV-1